Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

PHASE3TerminatedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

November 13, 2020

Study Completion Date

November 13, 2020

Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
DRUG

Etripamil NS 70 mg

All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.

DEVICE

Aptar Pharma Nasal Spray Bidose System

Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.

Trial Locations (34)

10065

Weill Cornell Medical Center, New York

14215

Trinity Medical WNY, PC, Buffalo

21237

MedStar Health Research Institute, Baltimore

28204

The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute, Charlotte

30309

Piedmont Heart Institute, Atlanta

31904

Columbus Regional Research Institute, Columbus

32169

Edgewater Medical Research, New Smyrna Beach

32207

Baptist Health Ambulatory Services, Jacksonville

32224

Mayo Clinic - Jacksonville, Jacksonville

45505

Heart House Research Foundation, LLC, Springfield

50266

Iowa Heart Center, West Des Moines

55902

Mayo Clinic, Rochester

57701

Black Hills Cardiovascular Research, Rapid City

72205

Arkansas Cardiology, Little Rock

77030

Baylor College of Medicine, Houston

78665

Baylor Scott and White Research Institute - Round Rock, Round Rock

80120

South Denver Cardiology Associates, P.C, Littleton

85016

Arizona Arrhythmia Research Center, Phoenix

90720

Los Alamitos Cardiovascular, Los Alamitos

312012

Georgia Arrythmia Consultants&Research Institute, Macon

07962

Atlantic Health System - Morristown Medical Center, Morristown

84157-7000

IHC Health Services Inc. DBA Intermountain Medical Center, Murray

T2N 4Z6

Libin Cardiovascular Institute of Alberta - University of Calgary, Calgary

T5H 3V9

Royal Alexandra Hospital, Edmonton

V5Z 1M9

Vancouver General Hospital - Research Institute ; Gordon and Leslie Diamond Health Centre, Vancouver

V8T 1Z4

Victoria Cardiac Arrhythmia Trials, Inc., Victoria

R2H 2A6

University of Manitoba, St Boniface General Hospital, Winnipeg

N1R 6V6

Cambridge Cardiac Care Centre, Cambridge

N1H 1B1

Dawson Road Medical Centre, Guelph

L8L 0A6

Hamilton Health Sciences, Hamilton

M2R 3V6

Partners in Advanced Cardiac Evaluation (PACE) Cardiology Clinic, Newmarket

M5B 1W8

St. Michael's Hospital, Toronto

H1T 1C8

Montreal Heart Institute - Institut de Cardiologie de Montréal, Montreal

J1H 5N4

CIUSSS de l'Estrie - CHUS ; Hôpital Fleurimont, Sherbrooke

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Milestone Pharmaceuticals Inc.

OTHER

NCT03635996 - Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 | Biotech Hunter | Biotech Hunter